Pliant Therapeutics, Inc. (PLRX) stock
PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.70−0.04 (-5.81%)
Close on Nov 13, 2026Market cap $43.16MP/E –Yield 0.00%
Pliant Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Pliant Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $63.83M, down 51.8% year over year. For fiscal 2025 it was $109.16M, down 35.5% from the year before. The highest annual figure on record is $169.31M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.16M | -35.5% |
| FY2024 | Dec 31, 2024 | $169.31M | +32.5% |
| FY2023 | Dec 31, 2023 | $127.80M | +31.8% |
| FY2022 | Dec 31, 2022 | $96.94M | +25.0% |
| FY2021 | Dec 31, 2021 | $77.55M | +17.2% |
| FY2020 | Dec 31, 2020 | $66.19M | +39.8% |
| FY2019 | Dec 31, 2019 | $47.35M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.93M | -0.0% |
| Q2 FY2026 | Jun 30, 2026 | $16.73M | -48.0% |
| Q1 FY2026 | Mar 31, 2026 | $13.58M | -68.7% |
| Q4 FY2025 | Dec 31, 2025 | $15.59M | -59.8% |
| Q3 FY2025 | Sep 30, 2025 | $17.94M | -62.4% |
| Q2 FY2025 | Jun 30, 2025 | $32.20M | -29.4% |
| Q1 FY2025 | Mar 31, 2025 | $43.44M | +16.9% |
| Q4 FY2024 | Dec 31, 2024 | $38.79M | +16.9% |
| Q3 FY2024 | Sep 30, 2024 | $47.75M | +47.7% |
| Q2 FY2024 | Jun 30, 2024 | $45.62M | +38.2% |
| Q1 FY2024 | Mar 31, 2024 | $37.15M | +26.9% |
| Q4 FY2023 | Dec 31, 2023 | $33.18M | +32.1% |
| Q3 FY2023 | Sep 30, 2023 | $32.34M | +31.4% |
| Q2 FY2023 | Jun 30, 2023 | $33.00M | +25.3% |
| Q1 FY2023 | Mar 31, 2023 | $29.27M | +40.2% |
| Q4 FY2022 | Dec 31, 2022 | $25.11M | +33.9% |
| Q3 FY2022 | Sep 30, 2022 | $24.61M | +16.9% |
| Q2 FY2022 | Jun 30, 2022 | $26.34M | +37.0% |
| Q1 FY2022 | Mar 31, 2022 | $20.88M | +12.7% |
| Q4 FY2021 | Dec 31, 2021 | $18.75M | +5.0% |
| Q3 FY2021 | Sep 30, 2021 | $21.05M | +24.7% |
| Q2 FY2021 | Jun 30, 2021 | $19.22M | +9.6% |
| Q1 FY2021 | Mar 31, 2021 | $18.53M | +33.1% |
| Q4 FY2020 | Dec 31, 2020 | $17.85M | +52.2% |
| Q3 FY2020 | Sep 30, 2020 | $16.88M | +56.6% |
| Q2 FY2020 | Jun 30, 2020 | $17.54M | +33.9% |
| Q1 FY2020 | Mar 31, 2020 | $13.92M | – |
| Q4 FY2019 | Dec 31, 2019 | $11.73M | – |
| Q3 FY2019 | Sep 30, 2019 | $10.78M | – |
| Q2 FY2019 | Jun 30, 2019 | $13.10M | – |
See a number that looks wrong?